Olema Oncology to Participate in Upcoming Investor Conferences
06 sept. 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 sept. 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Announces Combined Financing for Up to $180 Million
05 sept. 2023 07h30 HE
|
Olema Oncology
$130 million equity private placement led by Paradigm BioCapital with participation by Lightspeed Venture Partners, Deep Track Capital, BVF Partners L.P., Cormorant Asset Management, Vivo Capital,...
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
08 août 2023 16h03 HE
|
Olema Oncology
Initiation of OPERA-01 pivotal Phase 3 monotherapy clinical trial on track; expecting to enroll first patient in fourth quarterNew clinical data for palazestrant (OP-1250) to be presented in the...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 août 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
01 août 2023 08h00 HE
|
Olema Oncology
SAN FRANCISCO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juil. 2023 07h30 HE
|
Olema Oncology
SAN FRANCISCO, July 05, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 juin 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, June 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
30 mai 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, May 30, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
11 mai 2023 08h43 HE
|
Olema Oncology
OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction Overall...